Please login to the form below

Not currently logged in
Email:
Password:

Pharma news in brief

Our weekly round-up of the news in brief

EU should get tough on counterfeits
Tougher measures must be introduced in the European Union to stamp out trading of counterfeit drugs, according to a new report from Professor David Taylor from the University of London School of Pharmacy. Professor Taylor said that while the problem had originally been concentrated in developing countries, the global nature of the pharma industry means that patients everywhere are now at risk. In his report, which was launched at the House of Commons on November 29, he noted that the increased rationing of drugs could fuel the practice of counterfeiting. He has called for tougher legal penalties and better control of internet pharmacies, suggesting that because parallel trade, while not illegal, is difficult to monitor, it is attractive to counterfeiters. The report was funded by a grant from Pfizer.

HIV/AIDS drugs should be available in the workplace
The International Labour Organisation, part of the United Nations, has said that the workplace could offer the best setting to administer anti-retroviral (ARVs) drugs to people with HIV/AIDS. In a report published on World AIDS Day, the agency said that more than 24 million people in the global workforce in 2005 had HIV/AIDS, with 67 per cent living in Africa. The agency believes that ARVs should be made available in the workplace, estimating that 1.8 million more Africans could be alive in 2010 if 80 per cent of the workforce were treated with them.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics